Pfizer

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

ASCO26: Ivonescimab improves survival in NSCLC

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

Pfizer takes 25-valent Prevnar follow-up into phase 3

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

ADA: Lilly's weight-loss reveal, and wannabes display wares

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

ASCO26: Ivonescimab improves survival in NSCLC

Innovent in line for $10.5bn in Pfizer cancer alliance

Late-breakers to look out for at ASCO 2026

Pfizer takes 25-valent Prevnar follow-up into phase 3

Biosimilars & patient access independent of geographies or s...

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks